Intravenous Immunoglobulin (IVIG) remains the standard for treatment for CIDP. The ADHERE trial has recently confirmed the efficacy and safety of Efgartigimod in CIDP. Many other new therapies are being investigated.
CNO is involved in clinical trials looking at new and potentially more effective therapies for people living with CIDP.
Please inquire
As of writing CNO presently does not have any study recruiting
LTS 17261 ( SAR 445088/riliprubart)
Victorine Sikati Foko recruitment is closed
PDY 16744 study (phase II) 2021
